J&J Buys UK Biopharma Co. To Bolster Cardiovascular Line
New Jersey-based Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, has purchased U.K. virtual biopharmaceutical company XO1 Ltd. with an aim to add XO1's anticoagulant antibody drug to its cardiovascular portfolio, the...To view the full article, register now.
Already a subscriber? Click here to view full article